Literature DB >> 18463504

Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein.

Lixin Wang1, Sheila M Fleming, Marie-Françoise Chesselet, Yvette Taché.   

Abstract

The presynaptic protein alpha-synuclein (alphaSyn) has been implicated in both familial and sporadic forms of Parkinson's disease. We examined whether human alphaSyn-overexpressing mice under Thy1 promoter (Thy1-alphaSyn) display alterations of colonic function. Basal fecal output was decreased in Thy1-alphaSyn mice fed ad libitum. Fasted/refed Thy1-alphaSyn mice had a slower distal colonic transit than the wild-type mice, as monitored by 2.2-fold increase in time to expel an intracolonic bead and 2.9-fold higher colonic fecal content. By contrast, Thy1-alphaSyn mice had an increased fecal response to novelty stress and corticotropin releasing factor injected intraperipherally. These results indicate that Thy1-alphaSyn mice display altered basal and stress-stimulated propulsive colonic motility and will be a useful model to study gut dysfunction associated with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18463504      PMCID: PMC3108489          DOI: 10.1097/WNR.0b013e3282ffda5e

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  24 in total

Review 1.  The role of alpha-synuclein in Parkinson's disease: insights from animal models.

Authors:  Eleonora Maries; Biplob Dass; Timothy J Collier; Jeffrey H Kordower; Kathy Steece-Collier
Journal:  Nat Rev Neurosci       Date:  2003-09       Impact factor: 34.870

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

3.  Frequency of bowel movements and the future risk of Parkinson's disease.

Authors:  R D Abbott; H Petrovitch; L R White; K H Masaki; C M Tanner; J D Curb; A Grandinetti; P L Blanchette; J S Popper; G W Ross
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

4.  Colonic transit time and rectoanal videomanometry in Parkinson's disease.

Authors:  R Sakakibara; T Odaka; T Uchiyama; M Asahina; K Yamaguchi; T Yamaguchi; T Yamanishi; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

5.  Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.

Authors:  Stephen K Van Den Eeden; Caroline M Tanner; Allan L Bernstein; Robin D Fross; Amethyst Leimpeter; Daniel A Bloch; Lorene M Nelson
Journal:  Am J Epidemiol       Date:  2003-06-01       Impact factor: 4.897

Review 6.  In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?

Authors:  Marie-Francoise Chesselet
Journal:  Exp Neurol       Date:  2007-08-23       Impact factor: 5.330

7.  Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.

Authors:  Edward Rockenstein; Margaret Mallory; Makoto Hashimoto; David Song; Clifford W Shults; Ingrid Lang; Eliezer Masliah
Journal:  J Neurosci Res       Date:  2002-06-01       Impact factor: 4.164

8.  Transcriptional dysregulation in a transgenic model of Parkinson disease.

Authors:  Talene A Yacoubian; Ippolita Cantuti-Castelvetri; Bérengère Bouzou; Georgios Asteris; Pamela J McLean; Bradley T Hyman; David G Standaert
Journal:  Neurobiol Dis       Date:  2007-11-28       Impact factor: 5.996

9.  Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease.

Authors:  Grant Anderson; Ali Reza Noorian; Georgia Taylor; Mallappa Anitha; Doug Bernhard; Shanthi Srinivasan; James G Greene
Journal:  Exp Neurol       Date:  2007-05-18       Impact factor: 5.330

10.  Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease.

Authors:  V Lelievre; G Favrais; C Abad; H Adle-Biassette; Y Lu; P M Germano; G Cheung-Lau; J R Pisegna; P Gressens; G Lawson; J A Waschek
Journal:  Peptides       Date:  2007-05-18       Impact factor: 3.750

View more
  44 in total

1.  A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.

Authors:  Sheila M Fleming; Caitlin K Mulligan; Franziska Richter; Farzad Mortazavi; Vincent Lemesre; Carmen Frias; Chunni Zhu; Alistair Stewart; Illana Gozes; Bruce Morimoto; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2010-12-27       Impact factor: 4.314

Review 2.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

3.  Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation.

Authors:  L Wang; I Magen; P-Q Yuan; S R Subramaniam; F Richter; M-F Chesselet; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2012-07-11       Impact factor: 3.598

Review 4.  The bowel and beyond: the enteric nervous system in neurological disorders.

Authors:  Meenakshi Rao; Michael D Gershon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-07-20       Impact factor: 46.802

Review 5.  The aging colon: the role of enteric neurodegeneration in constipation.

Authors:  Brandt Wiskur; Beverley Greenwood-Van Meerveld
Journal:  Curr Gastroenterol Rep       Date:  2010-12

6.  Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein.

Authors:  Emily R Dirr; Osunde R Ekhator; Rachel Blackwood; John G Holden; Eliezer Masliah; Patrick J Schultheis; Sheila M Fleming
Journal:  Behav Brain Res       Date:  2018-02-03       Impact factor: 3.332

7.  Alpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway.

Authors:  Nanping Wu; Prasad R Joshi; Carlos Cepeda; Eliezer Masliah; Michael S Levine
Journal:  J Neurosci Res       Date:  2010-06       Impact factor: 4.164

Review 8.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

9.  Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein.

Authors:  Hoa A Lam; Nanping Wu; Ingrid Cely; Rachel L Kelly; Sindalana Hean; Franziska Richter; Iddo Magen; Carlos Cepeda; Larry C Ackerson; Wendy Walwyn; Eliezer Masliah; Marie-Françoise Chesselet; Michael S Levine; Nigel T Maidment
Journal:  J Neurosci Res       Date:  2011-04-12       Impact factor: 4.164

Review 10.  Enteric nervous system manifestations of neurodegenerative disease.

Authors:  Alcmène Chalazonitis; Meenakshi Rao
Journal:  Brain Res       Date:  2018-01-31       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.